Revive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to close out the year. Dr John Fahy, MD, MSc has joined the company as a scientific and clinical advisor to assist the company in the expansion and analysis of clinical data from the currently ongoing phase 3 clinical trial evaluating the safety and efficacy of Bucillamine against mild to moderate COVID-19.
A Professor of Medicine within the Division of Pulmonary and Critical Care Medicine at the Department of Medicine at The University of California San Francisco, Fahy has numerous roles within the field related to asthma, fibrosis, and other airway diseases. Such roles include the role of being the Michael S Stulbarg Endowed Chair in Pulmonary Medicine, as well as a director of UCSF Airway Clinical Research Center and UCSF’s severe asthma clinic.
Even more significantly, and perhaps more relevant to Revive Therapeutics, Fahy is the author of a study that was recently published, which is entitled, “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry.” The relevance here is that the study shows that thiol-based drugs, such as Bucillamine, decrease the binding of spike proteins related to COVID-19 to the receptor, decreasing the efficiency of the virus and inhibiting live virus infection. The study provided rationale to test thiol-based drugs, such as Bucillamine, as treatments against COVID-19.
“Dr. Fahy is a distinguished clinical researcher with thiol-based drugs, such as Bucillamine, and his understanding of its mechanism of action and how it relates to SARS-CoV-2 will be valuable in assessing our interim analysis of our FDA Phase 3 study.”
Michael Frank, CEO of Revive Therapeutics
Revive Therapeutics last traded at $0.57 on the CSE.
Sponsored · Selkirk Copper Mines
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
